Stock Financial Ratios, Dividends, Split History
TOL / Toll Brothers, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||5,990.90|
|Enterprise Value ($M)||5,488.52|
|Book Value ($M)||4,458.99|
|Book Value / Share||29.37|
|Price / Book||1.49|
|NCAV / Share||n/a|
|Price / NCAV||n/a|
|Common Stock Shares Outstanding||157,200,000|
|Weighted Average Number Of Diluted Shares Outstanding||169,487,000|
|Weighted Average Number Diluted Shares Outstanding Adjustment||2,147,000|
|Weighted Average Number Of Shares Outstanding Basic||162,222,000|
|Common Shares Outstanding||153,173,000|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||0.12|
|Return on Assets (ROA)||0.05|
|Return on Equity (ROE)||0.13|
|Identifiers and Descriptors|
|Central Index Key (CIK)||794170|
|889478953 889478905 889478903 76E993J50|
|SIC 1531 - Operative Builders|
Stock splits are used by Toll Brothers, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
Related News Stories
TOL got creamed, down 9.6% Tuesday, but for a mild "miss" on earnings and a report of future operational strength; almost boom times.
Juniper Networks (JNPR - Free Report) has extended its existing collaboration with Red Hat, Inc. (RHT - Free Report) , world's leading provider of open source solutions, to provide a unified solution for enterprises to ease their process of adopting cloud-native platforms. This initiative will involve tighter integration of Red Hat OpenShift Container platform and Red Hat OpenStack Platform with Juniper Contrail Enterprise Multicloud. (48-0)
Electronic Arts (EA - Free Report) recently acquired cloud gaming technology assets and personnel of a wholly owned subsidiary of Gamefly Inc. The takeover is in sync with the company’s focus on expansion of its streaming services, which it expects to launch within the next two to three years. EA has been developing infrastructure to offer streaming services for some time. Notably, the company had offered streaming services through partnership with Comcast’s (CMCSA - Free Report) Xfinity. (160-1)
Shares of Nasdaq Inc. (NDAQ - Free Report) hit a new 52-week high of $91.94 on May 22, banking on solid April volumes as well as strong first-quarter results. With about 0.9 million shares traded in the last session, the stock closed at $91.51, gaining 0.3%. Solid Q1 Results Nasdaq's bottom line of $1.24 outpaced the Zacks Consensus Estimate by 5.1% and improved 31% year over year on higher revenues, sturdy volumes, a lower tax incidence and solid market share. (42-0)
It is indeed a positive development that the trade war between the two biggest world economies United States and China has been put on hold. However, this has taken the luster away from gold, a safe haven for investors in turbulent times. (61-0)
as of ET